An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates

  title={An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates},
  author={Nerea Zabaleta and Wenlong Dai and Urja Bhatt and Jessica A. Chichester and Julio C. Sanmiguel and Reynette Estelien and Kristofer T. Michalson and Cheikh Diop and Dawid Maciorowski and Wenbin Qi and Elissa M. Hudspeth and Allison Cucalon and Cecilia Dyer and Maria Betina Pampena and James J. Knox and Regina C. LaRocque and Richelle C. Charles and Dan Li and Maya Kim and Abigail Sheridan and Nadia Storm and Rebecca I Johnson and Jared Feldman and Blake Marie Hauser and Aisling Ryan and Eric Zinn and Dione T. Kobayashi and Ruchi Chauhan and Marion McGlynn and Edward Thomas Ryan and Aaron G. Schmidt and Brian Price and Anna N. Honko and Anthony Griffiths and Sam Yaghmour and R. Hodge and Michael R. Betts and Mason W Freeman and James M. Wilson and Luk H. Vandenberghe},
  journal={Cell Host \& Microbe},
  pages={1437 - 1453.e8}

Single-dose AAV-based vaccine induces a high level of neutralizing antibodies against SARS-CoV-2 in rhesus macaques

The results showed that the NAbs were kept in high level and long lasting against authentic wild-type Sars-CoV-2, Beta, Delta and Omicron variants using plaque reduction neutralization test, and suggest that the vaccine has great potential to prevent the spread of SARS-Cov-2.

A protective AAV vaccine for SARS-CoV-2

The development of AAV-vectored COVID-19 vaccine candidates was initiated, and the potential of this AAV as a vaccine platform was explored, based on an engineered AAV variant that infects many types of cochlear cells.

Immunogenicity of an AAV-Based COVID-19 Vaccine in Murine Models of Obesity and Aging

The effectiveness of the AAVCOVID vaccine candidates in murine models of obesity and aging demonstrates that obesity did not significantly alter the immunogenicity of either vaccine candidate, and suggests that AAV-based vaccines may have limitations in older populations and may be equally applicable in obese and non-obese populations.

Viral vector-based vaccines against SARS-CoV-2

Adenovirus vector-based vaccines are the most advanced with several vaccines receiving Emergency Use Authorization (EUA) and vaccine candidates based on vaccinia virus and lentivirus vectors have been subjected to clinical evaluation.

Development of an Adeno-Associated Virus-Vectored SARS-CoV-2 Vaccine and Its Immunogenicity in Mice

The results of this study showed that the recombinant AAV9-RBD virus may be used for the development of a SARS-CoV-2 vaccine.

Induction of Hepatitis E Virus Anti-ORF3 Antibodies from Systemic Administration of a Muscle-Specific Adeno-Associated Virus (AAV) Vector

The novel AAVMYO3 capsid used in this study can serve as a versatile platform for the continued development of vector-based vaccines against HEV and other infectious agents, which could complement traditional vaccines akin to the current positive experience with SARS-CoV-2.

Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog

An update on the immunological and molecular race between AAV and its human host is provided, together with a compendium of state-of-the-art technologies which provide an advantage to A AV and which, thus, promise safer and more broadly applicable AAV gene therapies in the future.



Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques

Robust single-shot vaccine protection against SARS-CoV-2 in nonhuman primates is demonstrated and vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection.

An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques

A replication-incompetent adenovirus based vaccine expressing SARS-CoV-2 spike is generated, protection from infection in non-human primates is shown, and the immune response after intramuscular and intranasal vaccination is analyzed.

A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate

The quality of immune responses triggered and the rapid kinetics by which protective immunity can be mounted already after a single dose warrant further development of this potent SARS-CoV-2 vaccine candidate.

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

The initial evaluation in mice of two updated COVID-19 mRNA vaccines designed to target emerging SARS-CoV-2 variants demonstrated that a primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against the B.1.

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

Preliminary results in the subset of subjects who were enrolled with known SARS-CoV-2 seropositivity at baseline show that CVnCoV is also safe and well tolerated in this population, and is able to boost the pre-existing immune response even at low dose levels.

A Thermostable mRNA Vaccine against COVID-19

Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates

The efforts to utilize an mRNA platform for rational design and evaluations of mRNA vaccine candidates based on Spike (S) glycoprotein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are described, positioning MRT5500 as a viable vaccine candidate for clinical development against COVID-19.

Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model

These studies support the immune impact of INO-4800 for inducing both humoral and cellular arms of the adaptive immune system which are likely important for providing durable protection against COVID-19 disease.